UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D
Under the Securities Exchange Act of 1934
(Amendment No. 8)*
Crdentia Corp.
--------------
(Name of Issuer)
Common Stock, $0.0001 par value
-------------------------------
(Title of Class of Securities)
225235209
---------
(CUSIP Number)
Ann E. Carey, Business Legal Assistant
Howard Rice Nemerovski Canady Falk & Rabkin,
A Professional Corporation
Three Embarcadero Center, Suite 700
San Francisco, CA 94111-4024
(415) 434-1600
--------------------------------------------
(Name, Address and Telephone Number of Person Authorized to
Receive Notices and Communications)
September 30, 2006
------------------
(Date of Event which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G to
report the acquisition that is the subject of this Schedule 13D, and is
filing this schedule because of sections 240.13d-1(e), 240.13d-1(f) or
240.13d-1(g), check the following box. [ ]
Note: Schedules filed in paper format shall include a signed original and
five copies of the schedule, including all exhibits. See section 240.13d-
7 for other parties to whom copies are to be sent.
* The remainder of this cover page shall be filled out for a reporting
person's initial filing on this form with respect to the subject class of
securities, and for any subsequent amendment containing information which
would alter disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be
deemed to be "filed" for the purpose of Section 18 of the Securities
Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of
that section of the Act but shall be subject to all other provisions of
the Act (however, see the Notes).
CUSIP 225235209 SCHEDULE 13D Page 2 of 15
1. Names of Reporting MedCap Management & Research LLC
Persons.
I.R.S. Identification Nos. of above persons 94-3411543
(entities only).
2. Check the Appropriate Box if a Member of a Group (a) [ ]
(See Instructions)
(b) [ ]
3. SEC Use Only
4. Source of Funds (See Instructions) OO
5. Check if Disclosure of Legal Proceedings Is Required [ ]
Pursuant to Items 2(d) or 2(e)
6. Citizenship or Place of Organization Delaware
Number of 7. Sole Voting Power 11,176,769
Shares
Beneficially 8. Shared Voting Power 0
Owned by
Each 9. Sole Dispositive Power 11,176,769
Reporting
Person With 10. Shared Dispositive Power 0
11. Aggregate Amount Beneficially Owned by Each 11,176,769
Reporting Person
12. Check if the Aggregate Amount in Row (11) Excludes Certain [ ]
Shares (See Instructions)
13. Percent of Class Represented by Amount in Row 78%
(11)
14. Type of Reporting Person (See Instructions) IA
CUSIP 225235209 SCHEDULE 13D Page 3 of 15
1. Names of Reporting MedCap Partners L.P.
Persons.
I.R.S. Identification Nos. of above persons 94-3412423
(entities only).
2. Check the Appropriate Box if a Member of a Group (a) [ ]
(See Instructions)
(b) [ ]
3. SEC Use Only
4. Source of Funds (See Instructions) OO
5. Check if Disclosure of Legal Proceedings Is Required [ ]
Pursuant to Items 2(d) or 2(e)
6. Citizenship or Place of Organization Delaware
Number of 7. Sole Voting Power 10,999,519
Shares
Beneficially 8. Shared Voting Power 0
Owned by
Each 9. Sole Dispositive Power 10,999,519
Reporting
Person With 10. Shared Dispositive Power 0
11. Aggregate Amount Beneficially Owned by Each 10,999,519
Reporting Person
12. Check if the Aggregate Amount in Row (11) Excludes Certain [ ]
Shares (See Instructions)
13. Percent of Class Represented by Amount in Row 76.8%
(11)
14. Type of Reporting Person (See Instructions) PN
CUSIP 225235209 SCHEDULE 13D Page 4 of 15
1. Names of Reporting C. Fred Toney
Persons.
I.R.S. Identification Nos. of above persons
(entities only).
2. Check the Appropriate Box if a Member of a Group (a) [ ]
(See Instructions)
(b) [ ]
3. SEC Use Only
4. Source of Funds (See Instructions) OO
5. Check if Disclosure of Legal Proceedings Is Required [ ]
Pursuant to Items 2(d) or 2(e)
6. Citizenship or Place of Organization United States
Number of 7. Sole Voting Power 11,176,769
Shares
Beneficially 8. Shared Voting Power 0
Owned by
Each 9. Sole Dispositive Power 11,176,769
Reporting
Person With 10. Shared Dispositive Power 0
11. Aggregate Amount Beneficially Owned by Each 11,176,769
Reporting Person
12. Check if the Aggregate Amount in Row (11) Excludes Certain [ ]
Shares (See Instructions)
13. Percent of Class Represented by Amount in Row 78%
(11)
14. Type of Reporting Person (See Instructions) IN, HC
CUSIP 225235209 SCHEDULE 13D Page 5 of 15
Item 1. Security and Issuer
This Schedule 13D ("Schedule") relates to shares of common stock,
with par value $0.0001 (the "Common Stock"), of Crdentia Corp. (the
"Issuer"). The principal executive office of the Issuer is 5001 LBJ
Freeway, Suite 850, Dallas, TX 75244.
Item 2. Identity and Background
This Schedule is filed on behalf of MedCap Partners L.P. ("MedCap"),
MedCap Management & Research LLC ("MMR") and C. Fred Toney ("Toney"),
each of whose principal business office address is 500 Third Street,
Suite 535, San Francisco, CA 94107.
MedCap is an investment limited partnership, whose general partner is
MMR. MMR is an investment adviser registered under the laws of the State
of California. Toney is MMR's sole managing member. MMR is also the
general partner and investment manager of MedCap Master Fund, L.P., an
investment limited partnership ("MedCap Master"). MedCap Master is a
"master fund" and contains substantially all of the assets of a "feeder
fund," MedCap Partners Offshore, Ltd. ("MedCap Offshore")."
None of MedCap, MMR nor Toney has, during the past five years, been
convicted in any criminal proceeding (excluding traffic violations or
similar misdemeanors).
None of MedCap, MMR nor Toney has, during the past five years, been a
party to a civil proceeding of a judicial or administrative body of
competent jurisdiction, as a result of which any of them became or is
subject to a judgment, decree or final order enjoining future violations
of, or prohibiting or mandating activities subject to, federal or state
securities laws or finding any violation with respect to such laws.
MedCap is a Delaware limited partnership, MMR is a Delaware limited
liability company and Toney is a United States citizen.
Item 3. Source and Amount of Funds or Other Consideration
The source of funds to make the purchases described in Item 5(c) was
working capital of MedCap Master Fund, L.P. in the amount of
approximately $364,052.30.
Item 4. Purpose of Transaction
The acquisitions of Common Stock described in Item 5(c) were made
for investment purposes.
The agreement of limited partnership of MedCap provides MMR with
discretion to cause MedCap to make payments upon a withdrawal by a
limited partner in cash or in securities, or a combination of cash and
securities, or to segregate a portion of MedCap's assets equal to the
amount payable to the withdrawing limited partner and sell those assets
for the account of the withdrawn limited partner. Limited partners of
CUSIP 225235209 SCHEDULE 13D Page 6 of 15
MedCap have the right, upon written request, to receive a distribution of
the segregated assets. Effective September 30, 2006, MedCap segregated
some of the Issuer's Common Stock beneficially owned by MedCap into a
separate account for the benefit of some of MedCap's former limited
partners who have withdrawn from MedCap. MMR, as MedCap's general
partner, and Toney, as MMR's sole managing member, will continue to have
voting and dispositive control over the segregated shares of Common
Stock. Some of the withdrawn limited partners have requested
distribution to them of 255,893 shares of the segregated Common Stock
leaving, after distribution, 440,153 shares of Common Stock in the
segregated account. It is possible others may in the future request
additional distributions. MMR intends to cause MedCap to sell the
remaining segregated Common Stock in an orderly fashion and distribute
the proceeds to the withdrawn limited partners, subject to those limited
partners' right to request a distribution of the segregated Common Stock.
MMR and MedCap are not aware when MedCap will sell what portion of the
Common Stock or to what extent limited partners may in the future request
distribution to them of the Common Stock.
As previously disclosed on the Issuer's Current Report on Form 8-K
filed with the Securities and Exchange Commission on September 26, 2006,
the Issuer, iVOW Acquisition Corp., a Delaware corporation and wholly-
owned subsidiary of the Issuer ("Merger Sub") and iVOW, Inc., a Delaware
corporation ("iVOW"), have entered into an Agreement and Plan of Merger,
dated as of September 20, 2006 (the "Merger Agreement"), pursuant to
which Merger Sub will merge with and into iVOW, with iVOW surviving as a
wholly-owned subsidiary of the Issuer (the "Merger"). At the effective
time of the Merger, all shares of iVOW common stock issued and
outstanding immediately prior to the effective time will be converted
automatically into the right to receive, in the aggregate, approximately
$3.5 million in shares of the Issuer's Common Stock (based on the average
of the closing sale prices for Issuer's Common Stock for each of the 20
consecutive trading days ending the second complete trading day prior to
the effective time of the Merger, as reported on the OTC Bulletin Board),
subject to reduction based on the iVOW bank and financing debt assumed by
the Issuer, the value of any uncollected accounts receivable at the
effective time and the value of any iVOW warrants assumed by the Issuer.
Toney and MMR have beneficial ownership (through MedCap and MedCap
Master) of approximately 19.7% of iVOW's outstanding common stock (which
ownership has been separately reported on a Schedule 13D filed with the
Commission). Toney was also a member of the iVOW's Board of Directors
when the Merger Agreement was approved by the iVOW Board, but Toney has
voluntarily resigned from that position. Toney remains a member of the
Issuer's Board of Directors.
In connection with the execution of the Merger Agreement, each of the
Issuer and iVOW have entered into separate voting agreements (the "Voting
Agreements") with MedCap and MedCap Master, each dated September 20,
2006, pursuant to which MedCap and MedCap Master have agreed, among other
things, to vote all of the shares of the Issuer's Common Stock and the
CUSIP 225235209 SCHEDULE 13D Page 7 of 15
common stock of iVOW held by them in favor of the adoption of the Merger
Agreement. MedCap and MedCap Master have also agreed under the Voting
Agreements not to dispose of shares of the Issuer's Common Stock or the
common stock of iVOW, except as permitted thereunder.
Depending on market conditions and other factors, the reporting
persons may, at any time or from time to time, acquire additional
securities of the Issuer, or alternatively, may (if and to the extent
permitted under the Voting Agreements) dispose of some or all of the
securities of the Issuer beneficially owned by them (including but not
limited to the aforementioned segregated shares of Common Stock).
Except as described herein, the reporting persons do not currently
have any plans or proposals that relate to or would result in any of the
following:
(a) The acquisition by any person of additional securities of the
Issuer, or the disposition of securities of the Issuer;
(b) An extraordinary corporate transaction, such as a merger,
reorganization, or liquidation, involving the Issuer or any of its
subsidiaries;
(c) A sale or transfer of a material amount of assets of the Issuer
or any of its subsidiaries;
(d) Any change in the present board of directors or management of the
Issuer, including any plans or proposals to change the number or term of
directors or to fill any existing vacancies on the board;
(e) Any material change in the present capitalization or dividend
policy of the Issuer;
(f) Any other material change in the Issuer's business or corporate
structure;
(g) Changes in the Issuer's charter, bylaws or instruments
corresponding thereto or other actions which may impede the acquisition
of control of the Issuer by any person;
(h) Causing a class of securities of the Issuer to be delisted from a
national securities exchange or to cease to be authorized to be quoted in
an inter-dealer quotation system of a registered national securities
association;
(i) A class of equity securities of the issuer becoming eligible for
termination of registration pursuant to Section 12(g)(4) of the Act; or
(j) Any action similar to those enumerated above.
CUSIP 225235209 SCHEDULE 13D Page 8 of 15
Item 5. Interest in Securities of the Issuer
(a) As noted above, MedCap beneficially owns 10,999,519 shares of the
Issuer's Common Stock. The percentage of common stock
beneficially owned by MedCap for the purposes of this Schedule is
76.8%.
In addition to the securities beneficially owned through MedCap,
MMR and Toney beneficially own 177,250 shares of the Issuer's
Common Stock through MedCap Master. MedCap Master is a "master
fund" and contains substantially all of the assets of a "feeder
fund," MedCap Partners Offshore, Ltd. ("MedCap Offshore")
On October 24, 2006 all outstanding options held by Mr. Toney
terminated.
MMR, as general partner and investment manager of MedCap and
MedCap Master, and Toney, as the sole managing member of MMR, may
be deemed to beneficially own the shares owned by MedCap and
MedCap Master in that they may be deemed to have the power to
direct the voting or disposition of the shares. Neither the
filing of this Schedule nor any of its contents shall be deemed
to constitute an admission that either MMR or Toney is, for any
other purpose, the beneficial owner of any such securities to
which this Schedule relates, and MMR and Toney disclaim
beneficial ownership as to the Common Stock except to the extent
of their respective pecuniary interests therein. The percentage
of Common Stock beneficially owned by MMR and Toney for the
purposes of this Schedule is 78.0%.
The calculation of percentage of beneficial ownership in Item 11
of pages 2, 3 and 4 was derived from the Agreement and Plan of
Merger, dated September 20, 2006 among the Issuer, iVOW
Acquisition Corp. and iVOW, Inc,. included as Exhibit 2.1 to the
Issuer's Report on Form 8-K filed with the Securities and
Exchange Commission on September 26, 2006, in which the Issuer
stated that the number of shares of its Common Stock outstanding
as of September 20, 2006 was 14,329,966 shares.
The foregoing amounts do not include shares of the Issuer's
Common Stock issuable in respect of shares of the common stock of
iVOW outstanding at the effective time of the Merger (including
shares of iVOW common stock held by the reporting persons).
(b) Reference is made hereby to Items 7 to 10 of pages 2, 3 and 4 of
this Schedule, which Items are incorporated herein by reference.
CUSIP 225235209 SCHEDULE 13D Page 9 of 15
(c) The following transactions were effected during the 60 days prior
to the filing of this Schedule by persons named in response to
Item 4(a) above:
Number Price Where
Date of of per and How
Purchaser Transaction Shares Share Effected
MedCap Master and MedCap Offshore 9/26/06 8,000 $1.0557 Open Market
MedCap Master and MedCap Offshore 9/27/06 21,000 $1.5487 Open Market
MedCap Master and MedCap Offshore 9/28/06 55,000 $1.9055 Open Market
MedCap Master and MedCap Offshore 9/29/06 67,500 $2.8634 Open Market
MedCap Master and MedCap Offshore 10/03/06 4,500 $3.21 Open Market
See also the description of the segregation of shares of Common
Stock by MedCap and the Merger described in Item 4 above.
(d) Not applicable.
(e) Not applicable.
Item 6. Contracts, Arrangements, Understandings or Relationships with
Respect to Securities of the Issuer
MedCap is a party to an Amended and Restated Registration Rights
Agreement entitling it to registration rights with respect to Common
Stock issuable upon conversion of its shares of Series A Preferred Stock,
Series B-1 Preferred Stock and Series C Preferred Stock, including any
Series B-1 Preferred or Series C Preferred issued upon exercise of the
Warrants.
MedCap and the Issuer are also parties to the Letter Agreement, as
amended by the Letter Agreement Amendment, which amends in part the
Amended and Restated Registration Rights Agreement. Under the Letter
Agreement, the Issuer agrees to register for resale (i) all of the shares
of Common Stock and the Common Stock that can be acquired upon the
conversion of the Series C Preferred Stock that are held by MedCap and
(ii) shares of Common Stock underlying all of the warrants that MedCap
holds to acquire the Issuer's preferred stock; provided that, the Issuer
is not required to register for resale Common Stock underlying the
warrants unless such shares can be registered at the time that the shares
of Common Stock listed in item (i) are registered for resale.
MedCap was a party to two Secured Promissory Notes issued by the
Issuer, Baker Anderson Christie, Inc., Nurses Network, Inc., New Age
Staffing, Inc., PSR Nurses, Ltd., PSR Nurse Recruiting, Inc., PSR Nurses
Holdings Corp., CRDE Corp., Arizona Home Health Care/Private Duty, Inc.,
Care Pros Staffing, Inc., HIP Holding, Inc., Health Industry
Professionals, L.L.C., Travmed USA, Inc., Prime Staff, LP, Mint Medical
Staffing Odessa LP, and GHS Acquisition Corporation (collectively, the
"Issuer's subsidiaries") to MedCap (the "Secured Promissory Notes"). The
Issuer obtained a $500,000 loan from MedCap on November 15, 2005 and a
CUSIP 225235209 SCHEDULE 13D Page 10 of 15
$1,500,000 loan from MedCap on November 18, 2005 to fund working capital
needs. No equity securities and no securities exercisable, convertible
or exchangeable for equity securities were issued in connection with the
loans which were evidenced by the Secured Promissory Notes. In
connection with the loans, MedCap, the Issuer and the Issuer's
subsidiaries were parties to an Amended and Restated Security Agreement
pursuant to which MedCap was granted a subordinate security interest in
all of the assets and property of the Issuer and the Issuer's
subsidiaries. The Amended and Restated Security Agreement imposes
various restrictions on the activities of the Iasuer and the Issuer's
subsidiaries and includes events of default (with grace periods, as
applicable).
MedCap and the Issuer were parties to a Securities Purchase Agreement
dated as December 30, 2005 pursuant to which the Issuer issued 335,370
shares of its common stock to MedCap in consideration for the
cancellation of the principal and all accrued interest under the Secured
Promissory Notes. The shares were sold in a private transaction at a
price of $6.00 per share. In connection with the Securities Purchase
Agreement, the Issuer and MedCap entered into a Registration Rights
Agreement pursuant to which the Issuer agreed to register for resale on a
registration statement the shares acquired by MedCap under the Securities
Purchase Agreement.
MedCap and the Issuer are parties to a Subscription Agreement dated
March 3, 2006, pursuant to which the Issuer sold 25,000 shares of its
Common Stock to MedCap at a price of $8.00 per share in a private
transaction.
MedCap and the Issuer are parties to a Subscription Agreement dated
March 13, 2006, pursuant to which the Issuer sold 13,750 shares of its
Common Stock to MedCap at a price of $8.00 per share in a private
transaction.
MedCap Master and the Issuer are parties to a Subscription Agreement
dated March 13, 2006, pursuant to which the Issuer sold 11,250 shares of
its Common Stock to MedCap Master at a price of $8.00 per share in a
private transaction.
MedCap and the Issuer are parties to Subscription Agreement dated
April 3, 2006, pursuant to which the Issuer sold 58,333 shares of its
Common Stock to MedCap at a price of $6.00 per share in a private
transaction.
See the discussion of the Merger Agreement and the Voting Agreements
under Item 4 above.
CUSIP 225235209 SCHEDULE 13D Page 11 of 15
Item 7. Material to Be Filed as Exhibits
No. Exhibit
1. Agreement Regarding Joint Filing of Statement on Schedule 13D or
13G.
2. Amended and Restated Registration Rights Agreement between the
Issuer and MedCap dated August 30, 2004, as amended by the Letter
Agreement listed as Exhibit 3 below (included as Exhibit 2 to
MedCap's, MMR's and Toney's Schedule 13D/A No. 1 filed with the
Commission on September 3, 2004 and incorporated herein by
reference).
3. Letter Agreement dated March 29, 2005, between the Issuer and
MedCap (the "Letter Agreement") (included as Exhibit 3 to
MedCap's, MMR's and Toney's Schedule 13D/A No. 5 filed with the
Commission on April 11, 2005 and incorporated herein by
reference).
4. Amendment to Letter Agreement, dated May 2, 2005, between the
Issuer and MedCap (included as Exhibit 4 to MedCap's, MMR's and
Toney's Schedule 13D/A No. 6 filed with the Commission on May 10,
2005 and incorporated herein by reference).
5. Secured Promissory Note, dated November 15, 2005, issued by the
Issuer, Baker Anderson Christie, Inc., Nurses Network, Inc., New
Age Staffing, Inc., PSR Nurses, Ltd., PSR Nurse Recruiting, Inc.,
PSR Nurses Holdings Corp., CRDE Corp., Arizona Home Health
Care/Private Duty, Inc., Care Pros Staffing, Inc., HIP Holding,
Inc., Health Industry Professionals, L.L.C., Travmed USA, Inc.,
Prime Staff, LP, Mint Medical Staffing Odessa LP, and GHS
Acquisition Corporation to MedCap (included as Exhibit 10.1 to the
Issuer's Form 8-K filed with the Commission on November 21, 2005,
and incorporated herein by reference).
6. Secured Promissory Note, dated November 18, 2005, issued by the
Issuer, Baker Anderson Christie, Inc., Nurses Network, Inc., New
Age Staffing, Inc., PSR Nurses, Ltd., PSR Nurse Recruiting, Inc.,
PSR Nurses Holdings Corp.,
CRDE Corp., Arizona Home Health Care/Private Duty, Inc., Care Pros
Staffing, Inc., HIP Holding, Inc., Health Industry Professionals,
L.L.C., Travmed USA, Inc., Prime Staff, LP, Mint Medical Staffing
Odessa LP, and GHS Acquisition Corporation to MedCap (included as
Exhibit 10.2 to the Issuer's Form 8-K filed with the Commission on
November 21, 2005, and incorporated herein by reference).
CUSIP 225235209 SCHEDULE 13D Page 12 of 15
7. Amended and Restated Security Agreement, dated November 18, 2005,
by and among the Issuer, Baker Anderson Christie, Inc., Nurses
Network, Inc., New Age Staffing, Inc., PSR Nurses, Ltd., PSR Nurse
Recruiting, Inc., PSR Nurses Holdings Corp., CRDE Corp., Arizona
Home Health Care/Private Duty, Inc., Care Pros Staffing, Inc., HIP
Holding, Inc., Health Industry Professionals, L.L.C., Travmed USA,
Inc., Prime Staff, LP, Mint Medical Staffing Odessa LP, GHS
Acquisition Corporation and MedCap (included as Exhibit 10.3 to
the Issuer's Form 8-K filed with the Commission on November 21,
2005, and incorporated herein by reference).
8. Securities Purchase Agreement dated as of December 30, 2005 by and
between the Issuer and MedCap (included as Exhibit 10.1 to the
Issuer's Form 8-K filed with the Commission on January 6, 2006 and
incorporated herein by reference).
9. Registration Rights Agreement dated as of January 6, 2006 by and
between the Issuer and certain investors listed on the signature
pages thereto (included as Exhibit 10.5 to the Issuer's Form 8-K
filed with the Commission on January 10, 2006 and incorporated
herein by reference).
10. Subscription Agreement dated March 3, 2006 by and between the
Issuer and MedCap (included as Exhibit 10.1 to the Issuer's Form 8-
K filed with the Commission on March 7, 2006 and incorporated
herein by reference).
11. Subscription Agreement dated March 13, 2006 by and between the
Issuer and MedCap (included as Exhibit 11 to MedCap's, MMR's and
Toney's Schedule 13D/A No. 7 filed with the Commission on April
13, 2006 and incorporated herein by reference).
12. Subscription Agreement dated March 13, 2006 by and between the
Issuer and MedCap Master (included as Exhibit 12 to MedCap's,
MMR's and Toney's Schedule 13D/A No. 7 filed with the Commission
on April 13, 2006 and incorporated herein by reference).
13. Letter dated March 13, 2006, from the Board of Directors of the
Issuer to Holders of Series C and Warrants to Purchase Series B-1
and Series C Preferred Stock of the Issuer, in connection with the
Offer to Exchange Series C Preferred Stock and Warrants to
Purchase Series B-1 and Series C Preferred Stock in which the
Issuer has agreed to register the shares of Common Stock issued
pursuant to the Exchange on a suitable form and substantially in
compliance with the existing registration rights agreement
covering the Series C Stock and Series C Warrants within 60 days
of the completion of the Exchange Offer and to reimburse MedCap
for certain legal expenses incurred in connection with the
Exchange Offer (included as Exhibit 13 to MedCap's, MMR's and
Toney's Schedule 13D/A No. 7 filed with the Commission on April
13, 2006 and incorporated herein by reference).
CUSIP 225235209 SCHEDULE 13D Page 13 of 15
14. Subscription Agreement dated April 3, 2006 by and between the
Issuer and MedCap (included as Exhibit 14 to MedCap's, MMR's and
Toney's Schedule 13D/A No. 7 filed with the Commission on April
13, 2006 and incorporated herein by reference).
15. Agreement and Plan of Merger, dated September 20, 2006 among the
Issuer, iVOW Acquisition Corp. and iVOW, Inc. (included as Exhibit
2.1 to the Issuer's Current Report on Form 8-K filed with the
Commission on September 26, 2006 and incorporated herein by
reference).
16. Crdentia Merger Voting Agreement, dated September 20, 2006 among
the Issuer, MedCap Partners L.P. and MedCap Master Fund L.P.
(included as Exhibit 10.2 to the Issuer's Current Report on Form 8-
K filed with the Commission on September 26, 2006 and incorporated
herein by reference).
Signature
After reasonable inquiry and to the best of each of the undersigned's
respective knowledge and belief, each of the undersigned certifies that
the information set forth in this statement is true, complete and
correct.
Date November 3, 2006
/s/ C. Fred Toney
-----------------
Signature
Print Name C. FRED TONEY
MEDCAP PARTNERS L.P. MEDCAP MANAGEMENT & RESEARCH LLC
By its general partner
MedCap Management & Research LLC
By: /s/ C. Fred Toney By: /s/ C. Fred Toney
----------------- -----------------
Print Name C. Fred Toney Print C. Fred Toney
Title Managing Member Title Managing Member
CUSIP 225235209 SCHEDULE 13D Page 14 of 15
EXHIBITS LIST
Exhibit 1 Agreement Regarding Joint Filing of Statement on Schedule 13D
or 13G.
CUSIP 225235209 SCHEDULE 13D Page 15 of 15
EXHIBIT 1
AGREEMENT REGARDING JOINT FILING OF STATEMENT ON SCHEDULE 13D OR 13G
The undersigned agree to file jointly with the Securities and
Exchange Commission (the "SEC") any and all statements on Schedule 13D or
Schedule 13G (and any amendments or supplements thereto) required under
section 13(d) of the Securities Exchange Act of 1934, as amended, as to
the common stock of Crdentia Corp. For that purpose, the undersigned
hereby constitute and appoint C. Fred Toney as their true and lawful
agent and attorney-in-fact, with full power and authority for and on
behalf of the undersigned to prepare or cause to be prepared, sign, file
with the SEC and furnish to any other person all certificates,
instruments, agreements and documents necessary to comply with section
13(d) and section 16(a) of the Securities Exchange Act of 1934, as
amended, and to do and perform every act necessary and proper to be done
incident to the exercise of the foregoing power, as fully as the
undersigned might or could do if personally present.
Date November 3, 2006
/s/ C. Fred Toney
-----------------
Signature
Print Name C. FRED TONEY
MEDCAP PARTNERS L.P. MEDCAP MANAGEMENT & RESEARCH LLC
By its general partner
MedCap Management & Research LLC
By: /s/ C. Fred Toney By: /s/ C. Fred Toney
----------------- -----------------
Print Name C. Fred Toney Print C. Fred Toney
Title Managing Member Title Managing Member